

S. 3248, United States Anti-Doping Agency Reauthorization Act of 2020

 As ordered reported by the Senate Committee on Commerce, Science, and Transportation
 on March 11, 2020

By Fiscal Year, Millions of Dollars	2020	2020-2025	2020-2030
Direct Spending (Outlays)	0	0	0
Revenues	0	0	0
Increase or Decrease (-) in the Deficit	0	0	0
Spending Subject to Appropriation (Outlays)	0	83	175
Statutory pay-as-you-go procedures apply?	No	Mandate Effects	
Increases on-budget deficits in any of the four consecutive 10-year periods beginning in 2031?	No	Contains intergovernmental mandate?	No
		Contains private-sector mandate?	Yes, Under Threshold

S. 3248 would authorize the appropriation of \$175 million over the 2021-2029 period for the United States Anti-Doping Agency (USADA) to prevent the use of performance-enhancing drugs in Olympic sports. The bill also would require the Departments of Justice, Homeland Security, and Food and Drug Administration to coordinate with USADA on efforts to prevent the use of performance-enhancing drugs. Finally, the bill would require USADA to report on options to test horses for performance-enhancing drugs in the United States.

Assuming the appropriation of the authorized amounts, CBO estimates that implementing S. 3248 would cost \$83 million over the 2021-2025 period and \$175 million over the 2021-2030 period. For fiscal year 2020, USADA received an appropriation of \$10 million.

S. 3248 would impose private-sector mandates as defined in the Unfunded Mandates Reform Act (UMRA) on the USADA. The bill would require USADA to distribute educational materials to promote the positive values of youth sports and to report to the Congress on its capacity to implement an anti-doping and medication control program for horses. CBO estimates the cost of the mandate would not exceed the private-sector threshold established in UMRA (\$168 million in 2020, adjusted annually for inflation).

S. 3248 would not impose intergovernmental mandates as defined in UMRA.



**Table 1.
Estimated Increases in Spending Subject to Appropriation Under S. 3248**

	By Fiscal Year, Millions of Dollars											2020-2025	2020-2030
	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030		
Authorization	0	16	16	17	18	19	20	22	25	24	0	85	175
Estimated Outlays	0	14	16	17	18	18	20	22	25	24	1	83	175

Components may not sum to totals because of rounding.

On September 28, 2020, CBO transmitted a [cost estimate for H.R. 5373](#), the United States Anti-Doping Agency Reauthorization Act, as ordered reported by the House Committee on Energy and Commerce on September 9, 2020. The two pieces of legislation are similar; the differences in CBO's estimates reflect differences in the specified authorizations in the two bills.

The CBO staff contact for this estimate is Matthew Pickford (for federal costs) and Andrew Laughlin (for mandates). The estimate was reviewed by H. Samuel Papenfuss, Deputy Director of Budget Analysis.